Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. autoimmune disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This month
  • This Year
  • Older

Autoimmune Disease Articles & Analysis

109 news found

Neutrophils and Lactoferrin a key duo in inflammation

Neutrophils and Lactoferrin a key duo in inflammation

This limitation has made it difficult to fully grasp their contribution to health and disease. Recent scientific progress is now changing this picture. Researchers have developed innovative ways to study neutrophils by focusing on one of their most important components: lactoferrin. ...

ByBertin Technologies


CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

Therefore, flow cytometry is widely used in clinical diagnosis and medical research, such as tumor-associated diseases, autoimmune diseases, cardiovascular diseases, inflammatory infections and infectious diseases, providing higher clinical value for differential diagnosis, treatment monitoring and condition ...

ByCD Bioparticles


CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism

CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism

Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and malignancies. ...

ByCD BioSciences


CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. ...

ByCD Genomics


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...

ByCD ComputaBio


Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research

With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic antibodies covering a wide range of diseases, including infectious diseases, cardiovascular diseases, cancer and bone diseases, especially osteoporosis. In addition, Creative Diagnostics possesses a variety of ...

ByCreative Diagnostics


CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service

HLA regions are associated with the greatest number of human diseases in the human genome, and HLA typing is particularly important for assessing immune compatibility between organ donor and recipient pairs. There are more than 100 kinds of diseases related to HLA, involving autoimmune diseases, immunodeficiency ...

ByCD Genomics


First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

Biolojic Design also has partnerships with Nektar Therapeutics for the development of antibodies against autoimmune diseases and Eli Lilly for the development of antibodies that fight diabetes. ...

ByBiolojic Design, Ltd.


History of Health Technologies and Meaningful Change in the Era of Health 4.0

History of Health Technologies and Meaningful Change in the Era of Health 4.0

Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...

ByLifespin GmbH


CD Bioparticles Announces Magnetofection Reagents for Gene Expression

CD Bioparticles Announces Magnetofection Reagents for Gene Expression

Gene expression and therapy involves the introduction of foreign nucleic acids into target cells to modify or compensate for gene defects, thereby treating diseases such as cancer, diabetes, autoimmune diseases, and infectious diseases. ...

ByCD Bioparticles


Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development

Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development

Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...

ByCreative BioMart


Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

Jubilant Therapeutics Inc., a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to serve genetically defined patients suffering from cancer and autoimmune diseases, today announced that Syed Kazmi, Chief Executive Officer, will be making a business update presentation and meeting with institutional ...

ByJubilant Therapeutics Inc.


Eagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global ‘One Health’ Innovation

Eagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global ‘One Health’ Innovation

BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious diseases, immuno-oncology/autoimmune disease and metabolic health. Anthony Finbow, CEO, Eagle Genomics, said: “We are the pre-eminent platform business using next-generation graph technology and ...

ByEagle Genomics


Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

The analysis was carried out by researchers at Lund University and provides additional support for the application of the therapeutic diabetes vaccine Diamyd® to prevent or delay clinical type 1 diabetes, and aligns with the rationale of the VINNOVA-financed ASSET project (AI for Sustainable Prevention of Autoimmunity in the Society) coordinated by Diamyd Medical. ...

ByDiamyd Medical AB


iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Its FastPharming® Manufacturing System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and autoimmune diseases. The ...

ByIbio, Inc.


iBio acquires multiple assets of Al drug discovery partner RubrYc

iBio acquires multiple assets of Al drug discovery partner RubrYc

The other assets are two previously licensed candidates and three new immune-oncology therapeutic candidates, plus a partnership-ready PD-1 agonist for serious autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. ...

ByIbio, Inc.


iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

Unlike other traditional and newer AI-driven methods of drug discovery that often focus upon dominant epitopes, the RubrYc Discovery Engine uses predictive algorithms to identify and model subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Previously Licensed Candidates: All ...

ByIbio, Inc.


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

“These results are intriguing and while we cannot make defintive conclusions regarding efficacy, the response does appear quite positive compared to what we know about the disease progression in individuals diagnosed with LADA who display strong signs of autoimmunity”, says PhD Ingrid K Hals, Sponsor’s representative of the trial. ...

ByDiamyd Medical AB


The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis

The Wistar Institute and Jubilant Therapeutics Inc. Find PAD4 Inhibition in Neutrophils, Halts Cancer Progression and Metastasis

“These results highlight the potential of PAD4 inhibition as a novel treatment approach for cancer in addition to the previously established role of this pathway in autoimmune diseases," said Luca Rastelli, Ph.D., Chief Scientific Officer, Jubilant Therapeutics Inc. "We are developing several highly selective oral, small molecule PAD4 inhibitors, with the ...

ByJubilant Therapeutics Inc.


Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China

Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China

In the future, we will leverage Fosun Pharma’s advantages in the fields of kidney and blood system diseases and other therapeutic fields to improve the availability of medicines for patients and benefit more Chinese ...

ByShanghai Fosun Pharmaceutical (Group) Co. Ltd.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT